ERBB2 and breast carcinoma: Within the subset of estrogen receptor (ER) positive (N = 4,906) and within the subset of human epidermal growth factor 2 (HER2) positive (N = 1,580) breast cancer samples the MSLN amplification rate was 3% and 7%, respectively (Table 1).